| Teva Pharma AG - Seffalair Spiromax 232/14 mcg, Multidosenpulverinhalator |
| 67891 | | 03 | | Seffalair Spiromax 232/14 mcg | | Multidosenpulverinhalator | | R03AK06 | | Salmeterol and Fluticasone | | 12.04.2021 | | |
|
| Composition |
| fluticasoni propionas 202 µg, salmeterolum 12.75 µg ut salmeteroli xinafoas, lactosum monohydricum ad pulverem pro dosi, doses pro vase 60. |
| Packungsbestandteile |
| Multidosenpulverinhalator | | | | | | | | Active Agent | Dose |
|---|
| Fluticasoni Propionas | 202 µg | | Salmeterol | 12.75 µg |
| | BAG: Active Agent | Dose |
|---|
| Fluticasoni-17 Propionas | 202 mcg | | Salmeterol | 12.75 mcg |
| | | | Inactive agents |
|---|
| Lactose Monohydrate |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 003 | 60 | 55.49 | 76.75 | B | SL | Yes |
|
